Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells

Multidrug resistance-associated protein (MRP) mRNA expression and drug sensitivity in lung cancer cells were examined, and the effects of verapamil, a modulating agent for MRP, on drug sensitivity were also tested. Nine cell lines expressed various levels of MRP gene expression but not the MDR1 gene...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 17; no. 5A; p. 3493
Main Authors Narasaki, F, Oka, M, Fukuda, M, Ikeda, K, Terashi, K, Takatani, H, Nakamura, T, Soda, H, Kohno, S
Format Journal Article
LanguageEnglish
Published Greece 01.09.1997
Subjects
ATP-Binding Cassette Transporters - genetics
Cisplatin - pharmacology
Doxorubicin - pharmacology
Drug Resistance, Multiple
Etoposide - pharmacology
Gene Expression Regulation, Neoplastic - genetics
Genes, MDR
Humans
Lung Neoplasms
Multidrug Resistance-Associated Proteins
RNA, Messenger - genetics
Tumor Cells, Cultured - drug effects
Verapamil - pharmacology
Vincristine - pharmacology
Online AccessGet more information

Cover

More Information
Summary:Multidrug resistance-associated protein (MRP) mRNA expression and drug sensitivity in lung cancer cells were examined, and the effects of verapamil, a modulating agent for MRP, on drug sensitivity were also tested. Nine cell lines expressed various levels of MRP gene expression but not the MDR1 gene. The levels were higher in non-small cell carcinoma cells (NSCLC) than in small cell carcinoma cells (SCLC). Clear correlations between the MRP gene level and the sensitivity to etoposide (VP-16) and doxorubicin (Dox) were observed except for one cell line which highly expressed DNA topoisomerase II. Positive correlations between the MRP gene levels in three cell lines and the modulation effects of verapamil in VP-16, Dox, and vincristine were observed. The present results indicate that MRP probably confers intrinsic multidrug resistance in NSCLC rather than in SCLC.
ISSN:0250-7005